How this instrument works
Isotretinoin is an oral retinoid used to treat severe, treatment-resistant nodulocystic acne. Unlike most acne treatments, a full course of isotretinoin is dosed to a cumulative total over months rather than continued indefinitely, with the goal of durable remission after the course ends. Dosing is weight-based: treatment typically starts at a lower dose to assess tolerability, then titrates upward as the patient tolerates it, divided into two daily doses taken with food.
This calculator applies the commonly used weight-based dosing range — a starting dose of about 0.5 mg/kg/day, titrated up to a maximum of about 1.0 mg/kg/day as tolerated — along with a conventional cumulative dose target of 120 to 150 mg/kg spread across the full course, typically 15 to 20 weeks.
It's important to be precise about where the 120-150 mg/kg cumulative figure comes from: it is a long-standing clinical convention that has circulated in dermatology practice and older literature, not a number specified by the FDA drug label or mandated by current guidelines. The American Academy of Dermatology's 2024 acne management guideline does not specify one exact cumulative dose target, and some more recent evidence suggests comparable long-term remission rates can be achieved with lower cumulative totals in some patients. Treat the cumulative range shown here as a widely referenced convention to discuss with a supervising prescriber, not a regulatory requirement or a number that must be hit exactly.
Isotretinoin is highly teratogenic — it causes serious, well-documented birth defects if taken during pregnancy — and prescribing in the United States requires enrollment in the FDA-mandated iPLEDGE risk-management program, which includes pregnancy testing and contraception requirements for patients who can become pregnant. This calculator only performs the weight-based dosing arithmetic; it does not track iPLEDGE compliance, pregnancy testing schedules, or the other laboratory monitoring (such as lipid panels and liver function tests) that accompanies a real course of treatment. This is a reference tool for prescribers, not a substitute for a dermatologist's dosing plan and program enrollment.
- Enter the patient's weight in kilograms.
- Read the calculated starting dose in mg/day (0.5 mg/kg/day).
- Read the maximum titrated dose in mg/day (1.0 mg/kg/day), the ceiling to work toward as tolerated, not a starting point.
- Read the conventional cumulative dose range in mg (120-150 mg/kg) as a commonly referenced target for the full course — not an FDA-specified figure.
Worked example — a 65 kg patient
A 65 kg patient starting isotretinoin: the starting dose is 65 × 0.5 = 32.5 mg/day, typically split into two doses, taken with food to improve absorption.
As tolerated, the dose is titrated up toward a maximum of 65 × 1.0 = 65 mg/day.
The conventional cumulative target for the full course, at 120 to 150 mg/kg, works out to 65 × 120 = 7,800 mg on the low end and 65 × 150 = 9,750 mg on the high end — again, a widely used clinical convention rather than an FDA-mandated figure, and the actual course length and total dose a prescriber lands on can reasonably fall outside this range based on response and tolerability.
Questions
Is the 120-150 mg/kg cumulative dose an FDA requirement?
No. It's a long-standing clinical convention used in dermatology practice, not a figure specified in the FDA drug label. Current guidance, including the American Academy of Dermatology's 2024 acne guideline, does not mandate one specific cumulative dose target, and some newer evidence suggests similar durability of remission can be achieved with lower cumulative totals in some patients. It's best understood as a commonly referenced planning range, not a hard rule.
Why does dosing start low and increase gradually?
Starting at a lower dose (around 0.5 mg/kg/day) lets a prescriber assess how a patient tolerates common side effects — dry skin, dry lips, and other mucocutaneous effects are near-universal, and less common effects can also emerge — before titrating up toward the target dose (around 1.0 mg/kg/day) as tolerated. This graded approach is standard practice rather than starting everyone at the maximum dose.
Why is isotretinoin's teratogenicity such a major consideration?
Isotretinoin causes serious, well-established birth defects if taken during pregnancy, which is why prescribing in the United States requires enrollment in iPLEDGE, an FDA-mandated risk evaluation and mitigation strategy that includes pregnancy testing and contraception requirements for patients who can become pregnant. This calculator does not track iPLEDGE requirements or pregnancy testing schedules — it only computes the weight-based dosing numbers.
Who is this calculator for?
Prescribers — dermatologists and other clinicians managing a patient's isotretinoin course — as a quick weight-based dosing reference. It is not intended for patients to determine or adjust their own dose; isotretinoin dosing and monitoring require ongoing clinical supervision, laboratory monitoring, and program compliance.
Does hitting the exact cumulative target guarantee acne won't return?
No. Relapse can still occur even after completing a course at the conventional cumulative target, and conversely, some patients achieve durable remission at cumulative totals below 120 mg/kg. The cumulative dose is a useful planning reference, not a guarantee of outcome, and the decision to extend, shorten, or repeat a course is an individualized clinical judgment.
What other monitoring does a real isotretinoin course involve?
Beyond the weight-based dosing shown here, isotretinoin courses typically involve baseline and periodic monitoring such as lipid panels and liver function tests, mental health check-ins, and — for patients who can become pregnant — monthly pregnancy testing and contraception counseling under iPLEDGE. None of that monitoring is performed by this calculator, which only computes the dosing arithmetic.
References
- Reynolds RV, Yeung H, Cheng CE, et al. — Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-1006.e30 (PMID 38300170)
- FDA — iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) Program
Read this first: This instrument computes a screening figure from population formulas — it is not a diagnosis, and it cannot see the whole picture a clinician can. Use it to inform a conversation, not to replace one.